Assertio Holdings, Inc. (ASRT)
| Market Cap | 141.50M |
| Revenue (ttm) | 139.21M |
| Net Income (ttm) | 25.68M |
| Shares Out | 48.18M |
| EPS (ttm) | 0.53 |
| PE Ratio | 5.57 |
| Forward PE | 7.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 304,014 |
| Open | 2.94 |
| Previous Close | 2.91 |
| Day's Range | 2.9 - 3 |
| 52-Week Range | 1.26 - 4.44 |
| Beta | 1.67 |
| Analysts | Buy |
| Price Target | 6.12 (+107.5%) |
| Earnings Date | Nov 8, 2022 |
About ASRT
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, a... [Read more]
Financial Performance
In 2021, ASRT's revenue was $111.01 million, an increase of 4.46% compared to the previous year's $106.28 million. Losses were -$1.28 million, -95.45% less than in 2020.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for ASRT stock is "Buy." The 12-month stock price forecast is 6.12, which is an increase of 107.46% from the latest price.
News
ASRT vs. ZTS: Which Stock Is the Better Value Option?
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Should Value Investors Buy Assertio (ASRT) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
Assertio (ASRT) Q3 Earnings and Revenues Top Estimates
Assertio (ASRT) delivered earnings and revenue surprises of 14.29% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Assertio Reports Third Quarter 2022 Financial Results
Net Product Sales Increase 32% Year-Over-Year, Non-GAAP Adjusted EBITDA Increases 36% Increases Guidance for Net Product Sales and Adjusted EBITDA Debt Refinancing Extends Maturity, Reduces Cost and Inc...
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Are Investors Undervaluing Assertio (ASRT) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
Assertio Holdings, Inc. to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
LAKE FOREST, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients...
Assertio Holdings, Inc. Signs Exclusive License for Sympazan® (clobazam) Oral Film from Aquestive Therapeutics, Inc.
Trailing 12 Month Revenues of Sympazan Were $9.5 Million Assertio Paid $9.0 Million Upfront, Additional $6.0 Million upon Patent Allowance
The 7 Best Penny Stocks to Buy Now
As stocks remain in a bear market, even the best penny stocks continue to trade at depressed price levels. With macro uncertainties like inflation, rising interest rates, and a possible recession still ...
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
Here is how Assertio (ASRT) and Pliant Therapeutics, Inc. (PLRX) have performed compared to their sector so far this year.
ASRT or UTHR: Which Is the Better Value Stock Right Now?
ASRT vs. UTHR: Which Stock Is the Better Value Option?
Assertio to Participate in October 2022 Investor Conferences
LAKE FOREST, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients...
Here is What to Know Beyond Why Assertio Holdings, Inc. (ASRT) is a Trending Stock
Zacks.com users have recently been watching Assertio (ASRT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
ASRT vs. STVN: Which Stock Is the Better Value Option?
ASRT vs. STVN: Which Stock Is the Better Value Option?
Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?
Here is how Assertio (ASRT) and Humana (HUM) have performed compared to their sector so far this year.
The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market
These are seven of the best stocks to buy that can see substantial returns in the months ahead. Despite the ongoing worries on Wall Street, seasoned investors realize that there may be a bull market in ...
Is Trending Stock Assertio Holdings, Inc. (ASRT) a Buy Now?
Assertio (ASRT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Down 18.3% in 4 Weeks, Here's Why Assertio (ASRT) Looks Ripe for a Turnaround
Assertio (ASRT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co...
Assertio (ASRT) Flat As Market Sinks: What You Should Know
Assertio (ASRT) closed at $2.24 in the latest trading session, marking no change from the prior day.
ASRT vs. STVN: Which Stock Should Value Investors Buy Now?
ASRT vs. STVN: Which Stock Is the Better Value Option?
Is Most-Watched Stock Assertio Holdings, Inc. (ASRT) Worth Betting on Now?
Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.
Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?
Here is how Assertio (ASRT) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
Assertio to Participate in the 2022 Lake Street BIG6 Conference
LAKE FOREST, Ill., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patient...
Assertio (ASRT) Upgraded to Buy: Here's Why
Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ASRT or CORT: Which Is the Better Value Stock Right Now?
ASRT vs. CORT: Which Stock Is the Better Value Option?